Recent IPO activity and filings underscore robust access to public markets through late 2026. Multiple offerings priced in early October, including Retension Pharmaceuticals and TRex Bio, while Iambic Therapeutics and City Therapeutics are slated for mid-month trading amid a pipeline of biotech and fintech deals. Elevated Treasury yields near 5.3% have prompted selectivity and some postponements, yet investor demand supports smaller-to-mid-sized listings, with 2026 proceeds already exceeding prior-year totals excluding mega-deals. Key catalysts include Anthropic’s anticipated pre-Thanksgiving debut and additional S-1 filings, reinforcing trader consensus around near-term IPO resolution before 2027.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourView resolved






























Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes